학술논문
Risk factors for breakthrough invasive fungal infection during secondary prophylaxis
Document Type
Academic Journal
Author
Cornely, Oliver A.; Böhme, Angelika; Reichert, Dietmar; Reuter, Stefan; Maschmeyer, Georg; Maertens, Johan; Buchheidt, Dieter; Paluszewska, Monika; Arenz, Dorothee; Bethe, Ullrich; Effelsberg, Jenny; Lövenich, Harry; Sieniawski, Michal; Haas, Antje; Einsele, Hermann; Eimermacher, Hartmut; Martino, Rodrigo; Silling, Gerda; Hahn, Moritz; Wacker, Sidonie; Ullmann, Andrew J.; Karthaus, Meinolf
Source
Journal of Antimicrobial Chemotherapy. Apr 01, 2008 61(4):939-946
Subject
Language
English
ISSN
0305-7453
Abstract
BACKGROUND: Intensive chemotherapy with severe neutropenia is associated with invasive fungal infections (IFIs) leading to high mortality rates. During leukaemia induction chemotherapy, IFI often prohibited further curative treatment, thus predisposing for leukaemia relapse. Continuing myelosuppressive chemotherapy after diagnosis of IFI has become feasible with the now expanding arsenal of safe and effective antifungals. Secondary prophylaxis of IFI is widely administered, but reliable data on outcome and risk factors for recurrent IFI during subsequent chemotherapy are not available. This study determines risk factors for recurrent IFI in leukaemia patients. METHODS: From 25 European cancer centres, 166 consecutive patients with acute myelogenous leukaemia (AML) and a recent history of proven or probable pulmonary IFI were included. Patients were followed for recurrence or breakthrough IFI during the subsequent chemotherapy cycle. RESULTS: Of the 166 patients included, 69 (41.6%) were female, the median age was 53 years (range 2–81) the and 3 (1.8%) were <16 years. Recurrent IFI occurred in 26 patients (15.7%). Multiple logistic regressions yielded predisposing factors: duration of neutropenia [per additional day; odds ratio (OR) 1.043, confidence interval (CI) 1.008–1.078], high-dose cytarabine (OR 3.920, CI 1.120–12.706), number of antibiotics (per antibiotic; OR 1.504, CI 1.089–2.086), partial response as outcome of prior IFI (OR 4.037, CI 1.301–12.524) and newly diagnosed AML (OR 3.823, CI 0.953–15.340). Usage of high efficiency particulate air filter appeared protective (OR 0.198, CI 0.036–1.089). CONCLUSIONS: Duration of neutropenia, high-dose cytarabine, prior antibiotic therapy and a partial response to the first IFI therapy were risk factors for recurrent IFI and should be considered in AML patients with prior pulmonary IFI undergoing further chemotherapy.